SCM
EPZM

Sigma Capital Management’s Epizyme, Inc EPZM Stock Holding History

Sigma Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-130,000
Closed -$5.22M – 285
2013
Q3 		$5.22M Buy
+130,000
New +$4.4M 0.22% 123

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sigma Capital Management's EPZM Position: Q4 2013 in Review

Sigma Capital Management sold out of Epizyme, Inc (EPZM) in Q4 2013, closing a stake of 130,000 shares — an estimated $5.22M sold.

Sigma Capital Management first reported a position in EPZM in Q3 2013 and held it in 1 quarter. The position peaked at $5.22M in Q3 2013. 60 funds tracked by Wall St. Rank hold EPZM as of Q4 2013.

  • Sigma Capital Management reported no remaining Epizyme, Inc position as of Q4 2013 after selling out during the quarter.
  • Sigma Capital Management sold 130,000 Epizyme, Inc shares in Q4 2013, an estimated $5.22M.
  • Sigma Capital Management first reported a position in Epizyme, Inc in Q3 2013 and held it in 1 quarter.
  • Sigma Capital Management's Epizyme, Inc position peaked at $5.22M in Q3 2013.
  • 60 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2013.

Based on Sigma Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.